6 hours ago 1

AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense

Abdul Rahman

Mon, Jul 14, 2025, 10:30 AM 2 min read

AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company provided an update to its 2025 earnings guidance to account for a pre-tax acquired in-process research and development (IPR&D) and milestones expense of $823 million in the second quarter of 2025. This expense is expected to reduce both GAAP diluted earnings per share (EPS) and adjusted non-GAAP diluted EPS by $0.42 for the second quarter. Also, the company updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.67 to $11.87, incorporating the $823 million IPR&D expense.

AbbVie (ABBV) Updates 2025 EPS Guidance with $823M IPR&D Expense

A healthcare professional wearing a health communications device discussing patient data with a colleague.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, licensing agreements, and asset acquisitions. AbbVie stated that such costs are not routinely forecasted due to the uncertainty surrounding their timing and occurrence. This IPR&D expense is part of AbbVie’s broader strategy to bolster its pipeline through acquisitions and collaborations.

AbbVie Inc. (NYSE:ABBV) is a diversified healthcare company with a modest cannabis connection through its legacy drug, Marinol, a synthetic THC treatment for nausea and appetite loss. It also holds patents related to cannabis, including uses for cancer treatment, juvenile arthritis, and skin disorders.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.